ClinicalTrials.govpublic full text
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
small cell lung cancer extensive stage, atezolizumab, atezolizumab and hyaluronidase-tqjs, tumor suppressor gene 2 (tusc2), lipid nanoparticle (lnp), gene therapy, tecentriq, es-sclc, reqorsa, quaratusugene ozeplasmid, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 862357
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.